ArticleJournal of thrombosis and haemostasis : JTH2011
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
Article in Journal of thrombosis and haemostasis : JTH, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 129 citations in OpenAlex.
- Trial
- Haemostasis alterations in immune thrombocytopenia and their clinical significance.Research and practice in thrombosis and haemostasis · 2025Article
- Characteristics of Myelodysplastic Syndrome with Coagulation Abnormalities and Tailored Diagnosis and Treatment.Journal of personalized medicine · 2025Review
- Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.International journal of hematology · 2024Article
- Global hemostasis assays in acute myeloid leukemia: results of an observational prospective study.Blood transfusion = Trasfusione del sangue · 2024Observational
- Bleeding risk assessment in immune thrombocytopenia.Annals of hematology · 2023Article
- Review
- Megakaryocyte- and Platelet-Derived Microparticles as Novel Diagnostic and Prognostic Biomarkers for Immune Thrombocytopenia.Journal of clinical medicine · 2022Article
- Using Cryo-ET to distinguish platelets during pre-acute myeloid leukemia from steady state hematopoiesis.Communications biology · 2022Article
- Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.Frontiers in oncology · 2022Article
- Platelet Defects in Acute Myeloid Leukemia-Potential for Hemorrhagic Events.Journal of clinical medicine · 2021Article
- Review
- In Silico Methods for the Identification of Diagnostic and Favorable Prognostic Markers in Acute Myeloid Leukemia.International journal of molecular sciences · 2021Article
- Management of the Older Patient with Myelodysplastic Syndrome.Drugs & aging · 2021Review
- Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?Frontiers in medicine · 2021Review
- Severe Intracranial Hemorrhage at Initial Presentation of Acute Myelogenous Leukemia.Clinical practice and cases in emergency medicine · 2018Article
- Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia.Scientific reports · 2018Article
- Development and implementation of a novel immune thrombocytopenia bleeding score for dogs.Journal of veterinary internal medicine · 2018Article
- [Relative analysis of platelet activation with bleeding risk in patients with primary immune thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundSevere thrombocytopenia is a major risk factor for hemorrhage, but platelet function and bleeding risk at low platelet counts are poorly understood, because of the limitations of platelet function testing at very low platelet counts.
objectivesTo examine and compare platelet function in severely thrombocytopenic patients with acute myeloid leukemia (AML) or myelodysplasia (MDS) with that in patients with immune thrombocytopenia (ITP).
methodsWhole blood flow cytometric measurement of platelet activation and platelet reactivity to agonists was correlated with the immature platelet fraction (IPF) and bleeding symptoms.
resultsPatients with AML/MDS had smaller platelets, lower IPF and substantially lower platelet surface expression of activated glycoprotein (GP)IIb-IIIa and GPIb, both with and without addition of ex vivo ADP or thrombin receptor-activating peptide, than patients with ITP. In both ITP and AML/MDS patients, increased platelet surface GPIb on circulating platelets and expression of activated GPIIb-IIIa and GPIb on ex vivo activated platelets correlated with a higher IPF. Whereas platelet reactivity was higher for AML/MDS patients with bleeding than for those with no bleeding, platelet reactivity was lower for ITP patients with bleeding than for those with no bleeding.
conclusionsAML/MDS patients have lower in vivo platelet activation and ex vivo platelet reactivity than patients with ITP. The proportion of newly produced platelets correlates with the expression of platelet surface markers of activation. These differences might contribute to differences in bleeding tendency between AML/MDS and ITP patients. This study is the first to define differences in platelet function between AML/MDS patients and ITP patients with equivalent degrees of thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.